Epicardial adipose tissue (EAT) volume has been associated with coronary artery disease (CAD). As diabetes mellitus type 2 (DM2) patients have higher EAT volumes, it has been suggested that EAT may play a role in promoting CAD in these patients. The aim of this study was to examine the association between EAT and CAD in DM2, impaired fasting glucose (IFG) and control patients presenting with stable chest pain.
Introduction
Epicardial adipose tissue (EAT) has been proposed as a risk factor for coronary artery disease (CAD), 1 -3 as well as a predictor for the development of future cardiovascular events. 4 -6 Located between the myocardium and the visceral pericardium, EAT is visceral fat that directly surrounds the coronary arteries. It may work as an endocrine organ secreting hormones, bioactive adipocytokines, and chemokines, 7, 8 in this way promoting CAD. 1 Consequently, EAT may have a potential role as a parameter for risk stratification purposes in patients presenting with chest pain. For instance, in patients undergoing computed tomography (CT) calcium scoring, EAT could be easily assessed on the non-enhanced CT image, in this way potentially adding value to this diagnostic test. Patients with diabetes mellitus type 2 (DM2) and impaired fasting glucose (IFG) suffer from a two-to four-fold higher cardiovascular mortality compared with normoglycaemic patients. 9, 10 Also, patients with DM2 show a markedly increased prevalence of CAD. 11, 12 As both IFG and DM2 patients are reported to have higher EAT volumes, 13, 14 it is of particular interest to investigate the predictive value of EAT as a risk factor for CAD in these two patient categories. Therefore, the purpose of the present study is to examine the relation between EAT and CAD in DM2, IFG, and control patients with stable chest pain. Subsequently, we sought to establish whether EAT measurement offers additional value in predicting the risk of CAD beyond traditional cardiovascular risk factors in this patient category.
Methods

Study population
From December 2007 until June 2010, we prospectively included stable chest pain patients referred for coronary CT-angiography (CCTA) to rule out CAD. Included were patients with a recent history of atypical or typical chest pain, in which fasting serum was collected. Excluded were patients with unstable angina, haemodynamic instability, prior history of CAD, pregnancy, renal insufficiency (defined as serum creatinine .110 mmol/L), iodine allergy, or non-diagnostic CCTA. From 934 included patients, 78 had a non-diagnostic scan. Within the remaining study population, 83 patients had DM2 and 118 patients had IFG. From the remaining 655 patients, 209 randomly selected patients with normal fasting glucose levels served as the control population. Thus, the population studied consisted of 410 patients. Institutional Review Board and Ethics Committee approved the study and all patients signed informed consent prior to inclusion in the study.
Risk factor assessment
Clinical risk factors were prospectively assessed. Patients were defined as having DM2 according to the expert committee on the diagnosis and classification of diabetes mellitus. 15 IFG subjects were defined as those with fasting plasma glucose levels between 6.1 and 6.9 mmol/L. 15, 16 Control subjects were defined as those with fasting plasma glucose levels ,6.1 mmol/L and no family history of diabetes mellitus. Smoking was defined as current smoking. A positive family history was defined as having a first-degree relative with a history of myocardial infarction or sudden cardiac death before the age of 60. In addition to fasting glucose, total cholesterol, HDL, triglyceride, concentrations were measured using the Synchron LX20 (Beckman Coulter, Inc., Brea, CA, USA). Lowdensity lipoprotein (LDL) was calculated using the Friedewald equation, except for subjects with triglycerides .4.5 mmol/L or total cholesterol ,1.3 mmol/L, in which case LDL was determined on the Cobas Mira Plus (Roche Diagnostics, Basel, Switzerland).
CCTA acquisition
Scans were performed using a 64-slice multidetector-row CT scanner (Brilliance 64, Philips Healthcare, Best, The Netherlands) with a 64 × 0.625 mm slice collimation, a gantry rotation time of 420 ms, and a tube voltage of 120 kV. A non-enhanced scan was performed to determine the calcium score using the Agatston method. 17 This was followed by CCTA using 85 -110 mL of contrast agent (Xenetix 350, Guerbet, Roissy CdG Cedex, France), which was injected in the antecubital vein at 6.0 mL/s, directly followed by 40 mL of intravenous saline at 6.0 mL/s using a dual-head power injector. In patients with a heart rate ,65 bpm, a prospectively gated axial scan protocol was used, and in those with a heart rate .65 bpm, a retrospectively gated 'helical' protocol with dose modulation to obtain the best image quality at minimal radiation dose was performed. 18, 19 Tube current varied from 150 to 210 mAs and from 600 to 1000 mAs, for 'prospectively gated axial' and 'helical' protocols, respectively, depending on patients' weight and height. Patients received 5 -20 mg of metoprolol (AstraZeneca, Zoetermeer, The Netherlands) intravenously to lower the heart rate ,65 bpm as well as 0.8 mg sublingual nitroglycerin spray (Pohl-Boskamp, Hohenlockstedt, Germany).
Epicardial adipose tissue assessment
EAT volume was retrospectively measured using dedicated volumetric software (Volume, Leonardo, Siemens Healthcare, Erlangen, Germany). The most cranial slice taken into account was at the level of the carina and the caudal slice limit was identified as the last slice containing any portion of the heart. Within this area, we manually traced the pericardium every 1 cm, using the region of interest tool, to separate epicardial fat from pericardial fat. The software semiautomatically reconstructed the pericardium into a 3D region of interest, which was controlled visually and could be adjusted manually. Within this region of interest defined by the pericardium, contiguous 3D voxels between 2190 and 230 Hounsfield units were defined as fat voxels. 20 This resulted in a measurement of EAT in cm 3 . A prior study reported that threshold-based three-dimensional (3D) volumetric quantification of EAT has a good correlation (r ¼ 0.956, P , 0.001) with the 2D short-axis-based model and is less time consuming. 21 To determine the reproducibility of EAT measurements, the EAT volume was independently measured a second time by MV and RT, blinded from patient characteristics, in a subset of 20 patients.
Coronary assessment
Using the American Heart Association (AHA) 16 coronary segments model, 22 scans were independently analysed by an experienced cardiologist and a radiologist who were blinded to clinical information. The coronary artery tree was assessed using the source images on the provided software (Brilliance Workplace Portal v2.6.0.27, Philips Healthcare, Best, The Netherlands), and the degree of stenosis was visually defined as diameter stenosis (,50%), moderate (50 -70%), and severe diameter stenosis (.70%). Significant lesions were considered to be moderate or severe (one or more lesions with diameter stenosis ≥50%).
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An involvement score was calculated by counting all diseased vessel segments (irrespective of degree of stenosis), and the total score ranged from 0 to 16. 24 Plaques were categorized as calcified (exclusively content with density .130 Hounsfield units), non-calcified (exclusively content with density ,130 Hounsfield units), or mixed (characteristics of both calcified and non-calcified plaques).
Coronary artery disease outcome measures
Three different outcome measures for CAD were investigated.
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(1) Presence of any CAD; which was classified as a binary variable regarded positive if there was any plaque detected by CCTA, irrespective of stenoses or plaque morphology. (2) Presence of significant CAD; which was also a binary variable regarded positive in case of one or more coronary artery stenosis of at least 50% (as determined visually on CCTA). (3) Extent of CAD; measured by the previously described involvement score, i.e. the number of affected segments as determined by CCTA, again irrespective of stenosis severity or plaque morphology. This was also measured by the calcium score; this method was added to provide an additional measurement for the extent of CAD.
Statistical analysis
Data were analysed using SPSS version 17.0 (SPSS, Inc., Chicago, IL, USA). Continuous variables were reported as means + SD and proportions (%) were used for categorical values. Reproducibility was determined by calculating intra-class correlation coefficients (ICC), using a two-way mixed effects model, testing for absolute agreement. To assess differences between groups, ANOVA was used for continuous variables and Chi-square test for categorical variables. Univariable and multivariable analyses were performed using linear regression for continuous outcomes or binary logistic regression for dichotomous outcomes. All variables considered to be clinically relevant risk factors were entered into the multivariable models. Regression coefficients from multivariable analysis estimated the independent effect of variables entered into the model. The 95% confidence intervals (CIs) were used to evaluate whether the effects were statistically significant. Two-tailed P-values ,0.05 were used to indicate statistical significance.
Results
Study population
The mean age (+SD) was 57 + 11 years and 202 (49%) were male. The median EAT volume was 81 cm 3 . There were 262 (64%) patients with any CAD, of which 93 had a significant (≥50%) coronary stenosis. Baseline characteristics are presented in Table 1 . When the DM2 and IFG groups were compared with controls, they tended to be older, and had a higher BMI, higher systolic blood pressure, and lower serum cholesterol values (which was due to more statin use). In addition, EAT volumes, calcium scores, and involvement scores were higher, see Table 1 .
Reproducibility
The reproducibility of the 3D volumetric EAT quantification technique was excellent. The intra-observer variability was low: ICC: 0.93; P , 0.001, and the inter-observer agreement was good, ICC: 0.90; P , 0.001.
Glycaemic state and epicardial adipose tissue volume
Patients with DM2 and patients with IFG, both had significantly higher EAT volumes when compared with controls, see Figure 1 .
The mean EAT volumes of DM2 and IFG subjects, 98 + 41 and 92 + 39 cm 3 , respectively, were markedly .75 + 34 cm 3 in controls (P , 0.001). This association was independent of traditional cardiovascular risk factors when corrected for age, gender, BMI, systolic blood pressure, positive family history, and total cholesterol (P ¼ 0.04).
EAT as a predictor of CAD
Univariable analysis showed that the EAT volume predicted for the presence of any plaque on CCTA, but not for the presence of significant plaques (HR: 1.01, P , 0.001 and HR: 1.00, P ¼ 0.15, respectively). in 10 cm 3 EAT, the Agatston calcium score increased 6 units, and the involvement score increased with 0.13 segments (P ¼ 0.009 and P , 0.001, respectively). In addition, the association between EAT and the extent of CAD (involvement score) was investigated per glycaemic subgroup ( Table 3) .
Addition of EAT to glycaemic status
In addition to EAT, both DM2 and IFG were associated with the presence of CAD as well as the extent of CAD as determined by the involvement score (HR: 1.7, P ¼ 0.001 and B: 0.65, P , 0.001 for DM2, and HR 1.5, P ¼ 0.11 and B ¼ 0.54, P ¼ 0.05 for IFG). Interestingly, the number of patients with any CAD increased in the diabetic group if they also had a high EAT volume. Although not significant, 70% of diabetic patients with low EAT volumes (,80 cm 3 ) had evidence of at least some CAD; this fraction increased to 82% when the EAT volume was high (≥80 cm 3 ; P ¼ 0.22). For patients with IFG, these numbers were 65 and 67% (P ¼ 0.77). In the control group, 53% of patients with low EAT volumes had evidence of at least some CAD; this fraction increased to 63% when the EAT volume was high (P ¼ 0.13). When measuring the extent of CAD, a similar pattern was seen. For instance, in the control group the involvement score increased from 1.5 + 1.9 for low EAT volumes to 2.2 + 2.4 for high EAT volumes, P ¼ 0.04. Overall, the additive value of EAT volume over diabetic status for the prediction of CAD was low. The association between DM2 and the extent of CAD seemed stronger than between EAT and CAD, as is graphically shown in Figure 2 .
Multivariate analysis
As expected, the strongest independent predictors for the presence of CAD were traditional risk factors, such as age, male gender, smoking, and systolic blood pressure (Table 4) . Also, DM2 was an independent predictor for the extent of CAD, while EAT did not independently predict the presence or extent of CAD (as determined by the involvement score, see Table 5 ).
Plaque morphology
When investigating patients with at least one coronary plaque, we found DM2 patients to have a higher number of calcified plaques when compared with control patients (2.4 + 2.2 vs. 1.8 + 1.7, respectively, P ¼ 0.03). Concerning EAT, no differences in the number of calcified, mixed, or non-calcified plaques were found between EAT volume tertiles ( Figure 3) .
Discussion
In the current clinical study, we investigated the association between EAT, glycaemic state, and CAD in stable chest pain patients. First, we found that patients with DM2 and IFG showed significantly higher EAT volumes, independently of traditional risk factors including BMI. This finding is partly concurrent with previous research. 13, 14, 25 Secondly, we observed a clear association between EAT and the presence and extent of CAD in the total patient group. The magnitude of this association did not differ between glycaemic subgroups. However, EAT was not an independent predictor of CAD, while DM2 and other traditional risk factors were. So far, there is still a debate about the role of EAT as a cardiovascular risk factor. Reports suggesting EAT to be an independent risk factor for cardiovascular events are a large case -control study, 5 and a study using age-and sex-matched control groups. 6 On the other hand, several studies in which no independent association was found were published. 4, 14, 26 Regarding the association with CAD, our study design reflects a real-world clinical setting physicians find themselves confronted with, and provides relevant information about the value of different clinical risk factors in this patient category. Our data suggest that traditional risk factors, particular diabetic state, outweigh EAT as a risk factor for CAD. This observation is further supported by the strong correlation between glycaemic state and presence or extent of CAD. In perspective, a study by Graves et al. demonstrated the important correlation between glucose serum levels and the gravity of prognosis, even in non-diabetics. 27 Although we found the EAT volume to be associated with both the presence and extent of CAD, no relation between the EAT volume and the occurrence of stenotic coronary lesions could be demonstrated, which is in line with previous findings. 28 In the literature, the association between EAT and the calcium score was described before. 4 The calcium score is a generally accepted technique to measure the extent of CAD, and is known to confer important prognostic information. 29 A potential limitation of this technique is that it neglects the presence of non-calcified lesions. To overcome this, we reported the number of atherosclerotic segments involved in the total coronary tree as assessed by CCTA, resulting in a comprehensive scoring of the extent of CAD. Interestingly, the EAT volume was not associated with a specific type of plaque morphology in this study. Some morphological characteristics have been used to identify patients at higher risk for adverse cardiac events. 30 Although we investigated a larger population compared with most previous studies, our findings do not support previous observations that patients with high EAT volumes show more non-calcified or mixed plaques. 31, 32 Patients with DM2 status did show a higher amount of calcified plaques, which was in concurrence with previous findings. 33 Mechanistically, the EAT volume is closely related to central obesity, which in turn is strongly associated with both insulin resistance and atherosclerotic disease. This process has predominantly been attributed to the enhanced lipolytic activity of visceral fat cells. 34 Previously, strong associations between EAT volume and both visceral adipose tissue and BMI were demonstrated. The hypothesis that EAT has local pro-atherosclerotic effects is primarily based on its location directly surrounding the coronary arteries, together with its association with CAD. On the other hand, central obesity may lead to insulin resistance and DM2, resulting in systemically accelerated atherosclerotic effects. Some large studies indicate that central body fat outweighs or equals epicardial fat as a risk factor for atherosclerosis. 4, 25 In this case -control study, we have investigated the role of EAT as a clinical predictor for CAD in different glycaemic subgroups. Therefore, identifying causal mechanistic relationships was outside the scope of this investigation.
Limitations
The current study provides insight into the clinical relevance of EAT volume measurement in stable chest pain patients referred for CCTA. It is a single-centre study, investigating a limited number of patients. As we investigated a symptomatic patient group, these results might not be generally applicable. For instance, the EAT volume may show higher predictive value in other patient categories or asymptomatic subjects. Therefore, we cannot rule out that the EAT volume might improve residual risk stratification in certain populations. The endpoint of CAD was determined by CCTA. Especially for stenosis severity, it is not considered the gold standard and there is still a tendency for overestimation when compared with invasive angiography. As a cross-sectional study, it does not provide insight in the mechanisms behind the EAT volume and the extent of CAD. We did not measure waist circumference or visceral adipose tissue in this study, although this parameter is important for identification of local vs. systemic effects of adipose tissue. Instead we investigated traditional cardiovascular risk factors including BMI, which is a generally accepted parameter reflecting systemic body fat, and above all, widely used clinically. The mechanisms of the EAT volume potentially resulting in CAD and the role of DM2 in this process should be further investigated in larger clinical trials.
Conclusion
A clear association was found between the EAT volume and both presence and extent of CAD, in non-diabetic patients as well as in patients with IFG and DM2. However, EAT did not independently predict CAD in our population of stable chest pain patients. Traditional risk factors including DM2 status were the most important independent predictors for CAD. Therefore, the clinical application of EAT measurement in this patient category would not further benefit risk assessment of CAD at this moment.
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